June 27, 2025 10:28 AM EDT
China
Pharma

In­novent brings a new mech­a­nism to obe­si­ty mar­ket with Chi­na ap­proval

Elizabeth Cairns

Senior biopharma journalist

In­novent said on Fri­day that its obe­si­ty med­i­cine maz­du­tide has been ap­proved in Chi­na, be­com­ing the first dual GLP-1/glucagon ag­o­nist to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A din­ner in Paris re­vived talks for Sanofi's $9.5B deal for Blue­print

FDA head Makary’s short-lived CRL ask on KalVista’s drug rais­es more con­cerns of po­lit­i­cal in­ter­ven­tion

Al­pha­bet’s Cal­i­co inks $25M li­cens­ing deal for Mab­well’s IL-11 pro­grams

Bill Meury brings new per­spec­tive to In­cyte as Hop­penot re­tires; Ex-Mor­phoSys CEO leads re­vi­tal­ized Vor Bio

BioCryst sells Or­ladeyo busi­ness in Eu­rope; UCB gets a Phase 3 win for Fin­tepla

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times